本文關(guān)鍵詞： TPP 國際藥品貿(mào)易 知識產(chǎn)權(quán) 專利 數(shù)據(jù)獨占權(quán)　出處：《武漢大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：本文旨在研究跨太平洋伙伴關(guān)系協(xié)定(Trans-Pacific Partnership Agreement,TPP)下的藥品知識產(chǎn)權(quán)保護規(guī)則。目前,國內(nèi)外學(xué)者對TPP協(xié)定中藥品知識產(chǎn)權(quán)保護專章的研究取得了一定成果,但從總體上對TPP協(xié)定中知識產(chǎn)權(quán),特別是藥品專利權(quán)和試驗數(shù)據(jù)保護問題的研究還不夠充分。TPP協(xié)定是簽訂協(xié)議的發(fā)達國家與發(fā)展中國家相互妥協(xié)的產(chǎn)物,認真研究TPP協(xié)定中知識產(chǎn)權(quán)制度對中國更好地應(yīng)對藥品全球化趨勢、突圍發(fā)達國家專利防火墻并構(gòu)建中國特色國際貿(mào)易領(lǐng)域的藥品知識產(chǎn)權(quán)保護制度有著重要意義;隨著特朗普上臺及美國做出退出TPP協(xié)定的決定,TPP的未來似乎并不光明,TPP條款影響力或有所減弱,但已簽署TPP協(xié)定的國家仍在環(huán)太平洋地區(qū)藥品貿(mào)易中占有重要份額,也并不排除未來中國加入TPP的可能性,TPP協(xié)定條款仍將對全球藥品知識產(chǎn)權(quán)保護進程產(chǎn)生不可忽視的重要影響。本文共分為五章:第一章概述了國內(nèi)外的研究現(xiàn)狀,指出本文的研究方法與創(chuàng)新性,第二章概述了全球藥品貿(mào)易現(xiàn)狀與趨勢,闡述了藥品知識產(chǎn)權(quán)保護的定義和必要性,厘清本文的研究對象,確立本文的研究基礎(chǔ);第三章是對TPP協(xié)定中藥品知識產(chǎn)權(quán)保護條款主要內(nèi)容的翻譯、分析及研究,辨析了 TPP協(xié)定與現(xiàn)行國際條約特別是TRIPs協(xié)議中藥品知識產(chǎn)權(quán)保護的異同,凸顯了 TPP協(xié)定藥品知識產(chǎn)權(quán)保護條款的先進性,其對藥品的知識產(chǎn)權(quán)保護程度突破了傳統(tǒng)國際條約與國際協(xié)定的范疇,其嚴格性是史無前例的,是本文的核心內(nèi)容與價值所在;第四章對TPP與藥品相關(guān)規(guī)則的正負效應(yīng)做出評價;第五章詳述了 TPP協(xié)定藥品知識產(chǎn)權(quán)保護條款與我國規(guī)定的差異,對中國國際貿(mào)易協(xié)定中藥品知識產(chǎn)權(quán)保護條款的啟示,及其對中國中醫(yī)藥和仿制藥行業(yè)的影響,為中國應(yīng)對TPP協(xié)定中藥品知識產(chǎn)權(quán)保護高要求做鋪墊,為中國構(gòu)建和完善現(xiàn)行藥品貿(mào)易知識產(chǎn)權(quán)保護制度提出可能的解決方案。本文在借鑒前人研究成果的基礎(chǔ)上對藥品專利保護的概念和意義進行辨析,從專利權(quán)、藥品試驗數(shù)據(jù)保護與強制許可規(guī)定等方面研究了 TPP協(xié)定中藥品知識產(chǎn)權(quán)保護架構(gòu),探討TPP有關(guān)條款與現(xiàn)行國際條約的異同,并指出TPP協(xié)定知識產(chǎn)權(quán)專章中藥品專利保護條款的創(chuàng)新與不足之處,發(fā)掘TPP協(xié)定有關(guān)條款的對中國定立國際貿(mào)易協(xié)定中藥品知識產(chǎn)權(quán)保護條款的借鑒意義,力圖找出中國對TPP協(xié)定有關(guān)條款的應(yīng)對措施并加以完善。
[Abstract]:The purpose of this paper is to study the rules of pharmaceutical intellectual property protection under Trans-Pacific Partnership Agreement. At present, some achievements have been made by domestic and foreign scholars on the special chapter on the protection of pharmaceutical intellectual property rights in the TPP Agreement. However, the overall study of intellectual property rights in the TPP Agreement, especially the protection of drug patents and experimental data, is not enough. The agreement is a product of compromise between the developed and developing countries that have signed the agreement. It is of great significance for China to deal with the trend of drug globalization, break through the patent firewall of developed countries and construct the protection system of pharmaceutical intellectual property rights in the field of international trade with Chinese characteristics. With Trump taking power and the United States taking the decision to withdraw from the TPP, the future of the TPP does not seem to be bright or weakened, but the countries that have signed the TPP still account for an important share of the drug trade in the Pacific Rim. Nor does it rule out the possibility that China's accession to the TPP agreement will still have a significant impact on the process of global drug intellectual property rights protection. This paper is divided into five chapters: chapter one summarizes the current research situation at home and abroad. The second chapter summarizes the current situation and trend of global drug trade, expounds the definition and necessity of drug intellectual property protection, clarifies the research object of this paper, and establishes the research foundation of this paper. The third chapter is the translation, analysis and research of the main contents of the drug intellectual property rights protection clause in the TPP Agreement, and differentiates the similarities and differences between the TPP Agreement and the existing international treaties, especially the TRIPs agreement, on the protection of pharmaceutical intellectual property rights. It highlights the advanced nature of the pharmaceutical intellectual property protection clause in the TPP Agreement, and its degree of intellectual property protection for drugs breaks through the scope of traditional international treaties and international agreements, and its strictness is unprecedented. Chapter 4th evaluates the positive and negative effects of TPP and drug-related rules. Chapter 5th details the differences between the provisions of the TPP Agreement on the protection of pharmaceutical intellectual property rights and the provisions of China. The enlightenment to the protection of pharmaceutical intellectual property rights in China's international trade agreement, and its impact on Chinese traditional medicine and generic medicine industry, will pave the way for China to respond to the high requirements for the protection of pharmaceutical intellectual property rights in the TPP Agreement. This paper analyzes the concept and significance of drug patent protection on the basis of the previous research results, and analyzes the concept and significance of drug patent protection from the perspective of patent right in the light of the previous research results, and puts forward a possible solution for the construction and improvement of the current intellectual property protection system of drug trade in China. From the aspects of data protection and compulsory licensing of drug testing, this paper studies the framework of drug intellectual property protection in the TPP Agreement, and probes into the similarities and differences between the relevant provisions of TPP and the existing international treaties. It also points out the innovation and deficiency of the pharmaceutical patent protection clause in the intellectual property rights special chapter of the TPP Agreement, and explores the reference significance of the relevant provisions of the TPP Agreement for the protection of pharmaceutical intellectual property rights in the international trade agreement established by China. Try to find out China's response to the provisions of the TPP Agreement and improve it.
【學(xué)位授予單位】：武漢大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：D997.1

【參考文獻】

相關(guān)期刊論文 前10條

1 陳學(xué)宇;;《跨太平洋伙伴關(guān)系協(xié)定》中涉藥品監(jiān)管的知識產(chǎn)權(quán)條款研究[J];中國藥學(xué)雜志;2017年06期

2 宗艷霞;;TPP協(xié)議對我國外貿(mào)發(fā)展的影響及應(yīng)對策略——從TPP知識產(chǎn)權(quán)條款評析說起[J];對外經(jīng)貿(mào)實務(wù);2016年12期

3 丁錦希;任宏業(yè);姚雪芳;;TPP生物制品數(shù)據(jù)保護條款與中國政策定位研究[J];上海醫(yī)藥;2016年17期

4 董海珍;;針對TPP中知識產(chǎn)權(quán)條款我國知識產(chǎn)權(quán)存在的問題及對策研究[J];產(chǎn)權(quán)導(dǎo)刊;2016年09期

5 張乃根;;試析TPP知識產(chǎn)權(quán)條款的TRIPS追加義務(wù)[J];海關(guān)與經(jīng)貿(mào)研究;2016年04期

6 葉宗雄;;TPP協(xié)議與藥品有關(guān)的措施條款及其與中國相關(guān)法律的比較[J];電子知識產(chǎn)權(quán);2016年06期

7 張磊;夏瑋;;TPP生物藥品數(shù)據(jù)保護條款研究[J];知識產(chǎn)權(quán);2016年05期

8 謝青軼;;《跨太平洋伙伴關(guān)系協(xié)定》(TPP)的專利條款研究[J];知識產(chǎn)權(quán);2016年01期

9 周唯璇;;藥品試驗數(shù)據(jù)保護的發(fā)展趨勢及我國的應(yīng)對之策——從TRIPS到TPP[J];經(jīng)濟;2016年02期

10 劉鑫;;TPP背景下基因藥品專利池之構(gòu)建、管理與運行[J];電子知識產(chǎn)權(quán);2015年11期

相關(guān)碩士學(xué)位論文 前10條

1 孫康;Bolar例外條款研究[D];西南交通大學(xué);2016年

2 車慧晶;TPP藥品試驗數(shù)據(jù)保護問題研究[D];北京外國語大學(xué);2016年

3 王駿飛;藥品專利鏈接制度研究[D];南京大學(xué);2016年

4 朱麗娜;TPP協(xié)議中的知識產(chǎn)權(quán)條款分析[D];湖南大學(xué);2016年

5 王文璞;TPP協(xié)議中知識產(chǎn)權(quán)TRIPS-PLUS條款研究與中國知識產(chǎn)權(quán)法律應(yīng)對[D];寧夏大學(xué);2015年

6 鄭璐燕;Trips-plus下的藥品專利研究[D];寧波大學(xué);2014年

7 陳武;知識產(chǎn)權(quán)如何影響公共健康[D];華中科技大學(xué);2007年

8 李歡;公共健康危機引起的藥品可及性問題研究[D];湖南師范大學(xué);2006年

9 王團琴;WTO體制內(nèi)藥品專利保護與公共健康的沖突與協(xié)調(diào)[D];廈門大學(xué);2006年

10 蔣舸;TRIPS與公共健康需求的沖突與協(xié)調(diào)[D];武漢大學(xué);2005年

，

本文編號：1501528